Company & Sponsor Intelligence
Incyte Corporation
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials2
Recruiting0
Completed0
Countries1
Therapeutic footprint
parkinsons
Indexed studies
NCT03361228A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors
parkinsons · United StatesPHASE1,PHASE2
parkinsons · United StatesPHASE1,PHASE2
NCT03348904Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer
parkinsons · United StatesPHASE3
parkinsons · United StatesPHASE3
Intelligence layer updated: 2026-06-10 02:57:56.223123+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →